Revised SPC: Cyramza (ramucirumab) 10 mg/ml concentrate for solution for infusion

Ramucirumab is now licensed in combination with erlotinib for first-line treatment of adults with metastatic non-small cell lung cancer with activating epidermal growth factor receptor mutations. The entire SPC has been updated to include information relating to this indication.


electronic Medicines compendium